Oric Pharmaceuticals, Inc. (ORIC) — 10-Q Filings

10-Q Filings (6)

• ORIC Narrows Q3 Loss Amid Strategic Pipeline Focus, Workforce Cuts — Nov 13, 2025 Risk: high
  Oric Pharmaceuticals, Inc. (ORIC) reported a net loss of $32.587 million for the three months ended September 30, 2025, an improvement from a net loss of $34.56
• Oric Pharma's Q2 Loss Widens Amid Increased R&D, Bolstered Cash Reserves — Aug 12, 2025 Risk: medium
  Oric Pharmaceuticals, Inc. (ORIC) reported a net loss of $36.355 million for the three months ended June 30, 2025, an increase from a net loss of $31.963 millio
• Oric Pharmaceuticals Files Q1 2025 10-Q — May 5, 2025 Risk: medium
  Oric Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its business oper
• Oric Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Oric Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial position, including assets and liabilitie
• Oric Pharmaceuticals Files Q2 2024 10-Q — Aug 12, 2024 Risk: low
  Oric Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information, including fair value measurements for v
• Oric Pharmaceuticals Files 10-Q for Period Ending March 31, 2024 — May 6, 2024 Risk: low
  Oric Pharmaceuticals, Inc. (ORIC) filed a Quarterly Report (10-Q) with the SEC on May 6, 2024. Oric Pharmaceuticals, Inc. filed a 10-Q report for the quarter en

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX